ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO904

SGLT2i Prescribers Among CKD Patients: Trends in Real-World Data (RWD)

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention


  • Stavas, Joseph, ProKidney, Raleigh, North Carolina, United States
  • Butler, Emily Lynn, ProKidney, Raleigh, North Carolina, United States
  • Abdelhadi, Jenna, Aetion, New York, New York, United States
  • Zhang, Tancy C., Aetion, New York, New York, United States
  • Rubens, Lexie, Aetion, New York, New York, United States
  • Irwin, Debra E., Aetion, New York, New York, United States

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) reduce CKD risks. RWD may provide insight into early adopters of these agents and treatment trends for CKD due to Type 2 Diabetes (T2DKD).


Adults ≥30 years old with ≥2 eGFR tests, 90-365 days apart, classifying patients as CKD stages 2-4 were identified in the HealthVerity PrivateSource20 closed claims linked with Veradigm Health Insights EHR and Quest laboratory results data between 1/1/2018 and 09/30/2021. The first eGFR test date was the index date, patients were followed for initiation of SGLT2i and the provider type on the prescription claim was identified. Patients with AKI and SGLT2i prescriptions during baseline were excluded.


5.1% of CKD patients (7094/137,874) Stages 2-4 initiated SGLT2i therapy and the number of CKD patients initiating treatment increased over the study period until 2020 (Fig 1). 94% of new SGLT2i use was among T2DKD. SGLT2i initiation was highest in Stage 2 and 3 (5.8%, 4.1%) followed by Stage 4 (1.5%). As disease severity worsened, the proportion of prescriptions initiated by nephrologists increased (0.7% Stage 2 vs.19.7% Stage 4). Four specialty groups comprised 79% of prescribers overall, with General Medicine (59%) and Endocrinologists (16%) being the early prescribers, while the proportion of Nephrologists and Cardiologists was low but slightly grew by 2021 (Fig 2).


RWD indicates sparse initiation of SGLT2i in CKD patients, with increasing trends until 2020 which may, in part, be COVID-19 related. General Medicine and Endocrinologists were consistently the most common prescribing providers, while Nephrologist prescriptions increased over time and as stage advanced.

Fig. 1

Fig. 2


  • Commercial Support –